 |
|
|
|
|
|
|
|
|
|
|
|
1 to 8 of 8 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Guenette S. on PAPER: Deyts C. et al., 2012, This is an excellent study. Not only is the novel interaction of APP/APLP C-terminal fragments... 14 Feb 2012.
|
|
|
 |
|
|
Guenette S. on PAPER: Freude KK. et al., 2011, This paper shows that human embryonic stem (hES) cells overexpressing amyloid precursor protein... 9 Jun 2011.
|
|
|
|
|
|
Guenette S. on PAPER: Li H. et al., 2010, This interesting study from Hui Zheng’s lab shows that the cytosolic APP C-terminal domain is... 13 Aug 2010.
|
|
|
|
|
|
Guenette S. on NEWS: Keystone: Death Receptor Ligand—New Role for APP, New Model for AD?, This is a compelling study that provides a biological “raison d’être” for an N-terminal secreted... 4 Mar 2009.
|
|
|
|
|
|
Guenette S. on PAPER: Bai Y. et al., 2008, Bai et al. use a novel approach for identifying APP family member-candidate interacting... 18 Feb 2008.
|
|
|
|
|
|
Guenette S. on PAPER: Ring S. et al., 2007, This is a carefully crafted and cautiously interpreted study showing that the α-secretase... 14 Aug 2007.
|
|
|
|
|
|
Guenette S. on PAPER: Ma H. et al., 2007, This intriguing study from Karen Ashe’s lab shows that mice overproducing wild-type human APP... 11 May 2007.
|
|
|
|
|
|
Guenette S. on PAPER: Minopoli G. et al., 2007, This is an interesting study showing that loss of Fe65 increases susceptibility to DNA damage in... 8 Dec 2006.
|
|
|
|
|
|
|
1 to 8 of 8 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
Check out our upcoming Webinar: 
